Annals of Oncology Advance Access originally published online on April 27, 2005
Annals of Oncology 2005 16(8):1305-1310; doi:10.1093/annonc/mdi244
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
© 2005 European Society for Medical Oncology
Mucinous histology predicts for reduced fluorouracil responsiveness and survival in advanced colorectal cancer
1 Department of Medicine, 2 Department of Histopathology, 3 Department of Computing and Information, Royal Marsden Hospital, London and Sutton, Surrey, UK
* Correspondence to: Prof. D. Cunningham, Department of Medicine, Royal Marsden Hospital, Downs Road, Sutton, Surrey SM2 5PT, UK. Tel: +44-208-661-3156; Fax: +44-208-643-9414; Email: david.cunningham{at}icr.ac.uk
Background:: Mucinous carcinoma of the colon and rectum (mucinous CRC) is a histological subtype of colorectal adenocarcinoma for which there is little data on chemotherapy responsiveness. The purpose of this study was to investigate specifically the efficacy of fluorouracil-based first-line chemotherapy in patients with advanced mucinous CRC.
Patients and methods:: All patients with advanced mucinous CRC enrolled in three prospective randomized trials evaluating infused 5-fluorouracil as first-line treatment were compared with patients with non-mucinous subtypes enrolled in the same trials in a case–control study. Prognostic factors associated with overall response rate (ORR), progression-free survival (PFS) and overall survival (OS) were identified using univariate and multivariate logistic and/or Cox proportional hazards analyses.
Results:: The study included 135 patients (45 cases and 90 controls). The response rates for cases and controls were 22% [95% confidence interval (CI), 11% to 38%] and 47% (95% CI, 36.1% to 58.2%), respectively (P=0.0058). Median OS for the mucinous CRC patients was 11.8 months (95% CI, 8.87–14.8) compared with 17.9 months (95% CI, 13.38–22.39) in the control group (univariate analysis, P=0.056); after correcting for significant prognostic factors by multivariate Cox regression analysis, P=0.0372 and hazard ratio (HR)=1.497 (1.02–2.19).
Conclusion:: Patients with advanced mucinous CRC have a poorer response to fluorouracil-based first-line chemotherapy and reduced survival compared with patients with non-mucinous CRC.
Key words: colorectal cancer, 5-fluorouracil, mucinous
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  K. Okoshi, S. Nagayama, M. Furu, Y. Mori, A. Yoshizawa, J. Toguchida, and Y. Sakai A Case Report of Pathologically Complete Response of a Huge Rectal Cancer after Systemic Chemotherapy with mFOLFOX6 Jpn. J. Clin. Oncol., June 2, 2009; (2009) hyp045v1. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Ruzzo, F. Graziano, F. Loupakis, E. Rulli, E. Canestrari, D. Santini, V. Catalano, R. Ficarelli, P. Maltese, R. Bisonni, et al. Pharmacogenetic Profiling in Patients With Advanced Colorectal Cancer Treated With First-Line FOLFOX-4 Chemotherapy J. Clin. Oncol., April 1, 2007; 25(10): 1247 - 1254. [Abstract] [Full Text] [PDF]
|
|